Pancreatic Cell News 10.21 June 4, 2019 | |
| |
TOP STORYInteraction with Stromal Cells Influences Tumor Growth, Metastasis in Pancreatic Cancer Researchers demonstrated how the response to pancreatic cancer cells of normal tissue – called the stroma – within tumors could influence the ability of individual cancer cells to proliferate and metastasize. Their report may lead to improved therapies for this difficult-to-treat cancer. [Press release from Massachusetts General Hospital discussing online prepublication in Cell] Press Release | Abstract | Graphical Abstract | |
| |
PUBLICATIONS(Ranked by impact factor of the journal)DIABETES & PANCREATITISAcceleration of β Cell Aging Determines Diabetes and Senolysis Improves Disease Outcomes Senolysis, using either a transgenic INK-ATTAC model or oral ABT263, improved glucose metabolism and β cell function while decreasing expression of markers of aging, senescence, and senescence-associated secretory profile. [Cell Metab] Abstract | Graphical Abstract Scientists explored whether combining oncogenic KrasG12D mutation with an additional gene mutation known to occur in human intraductal papillary mucinous neoplasms (IPMN) could induce IPMN from pancreatic duct cells. [Gut] Abstract Massive Single-Cell mRNA Profiling Reveals a Detailed Roadmap for Pancreatic Endocrinogenesis The authors generated a novel Neurogenin3 (Ngn3)-Venus fusion (NVF) reporter mouse line, that closely mirrored the transient endogenous Ngn3 protein expression. To define an in vivo roadmap of endocrinogenesis, they performed single-cell RNA-sequencing of 36,351 pancreatic epithelial and NVF+ cells during secondary transition. [Development] Abstract An in vitro study using a pancreatic beta cell line showed that tacrolimus treatment increased apoptosis and the production of mitochondrial reactive oxygen species, while cotreatment with coenzyme Q10 effectively attenuated these alterations. [Sci Rep] Full Article PANCREATIC CANCERTGIF1 Functions as a Tumor Suppressor in Pancreatic Ductal Adenocarcinoma Mechanistic experiments showed that TGIF1 associated with Twist1 and inhibited Twist1 expression and activity, and this function was suppressed in the vast majority of human pancreatic ductal adenocarcinomas by KrasG12D/MAPK-mediated TGIF1 phosphorylation. [EMBO J] Abstract To understand how exosomes might contribute to cell transformation, investigators utilized the classic two-step NIH/3T3 cell transformation assay and observed that exosomes isolated from pancreatic cancer cells, but not normal human cells, could initiate malignant cell transformation and these transformed cells formed tumors in vivo. [eLife] Full Article In cell line-derived xenografts, the net tumor growth compared to controls was significantly reduced by nab-paclitaxel (NPT)+gemcitabine (Gem), NPT+Gem + MK-2206 (MK), NPT+Gem + trametinib (Tra) and NPT+Gem+MK+Tra therapies. In patient-derived xenografts, the combination of MK-2206 and trametinib with chemotherapy had an additive response in reducing tumor growth. [Cancer Lett] Abstract Hydroxychavicol (HC) induced DNA damage, as evidenced by γ-H2AX, 53BP1 induction and comet assay, which further resulted in mitotic catastrophe and apoptosis. The apoptosis induced by HC was JNK pathway-dependent and caspase-mediated. [Biochem Pharmacol] Abstract | Graphical Abstract The functional roles of PIN1 in pancreatic ductal adenocarcinoma were explored in vitro and in vivo using both genetic and chemical PIN1 inhibition. Researchers showed PIN1 was upregulated in pancreatic cancer and metastatic tissues. [Cancer Sci] Abstract Subscribe to one of our other 19 science newsletters such as Hepatic Cell News & Intestinal Cell News. | |
| |
REVIEWSA Century of Diabetes Technology: Signals, Models, and Artificial Pancreas Control The author recounts briefly the story of diabetes technology, which began a century ago with the discovery of insulin, progressed through glucose monitoring and subcutaneous insulin delivery, and is now rapidly advancing towards fully automated clinically viable artificial pancreas systems. [Trends Endocrinol Metab] Abstract Cellular Determinants and Therapeutic Implications of Inflammation in Pancreatic Cancer Investigators describe the current understanding of key determinants of inflammation in pancreatic ductal adenocarcinoma; mechanisms by which inflammation drives immune suppression; the impact of inflammation on metastasis, therapeutic resistance, and clinical outcomes; and strategies to intervene on inflammation for providing therapeutic benefit. [Pharmacol Ther] Abstract Visit our reviews page to see a complete list of reviews in the pancreatic cell research field. | |
| |
SCIENCE NEWSLexicon Pharmaceuticals to Present New Clinical Data Lexicon Pharmaceuticals, Inc. announced new analyses of clinical data for sotagliflozin will be presented. The five accepted posters reflect Lexicon and its collaborator, Sanofi’s efforts to address the unmet need and potential treatment options for the management of type 1 diabetes. [Press release from Lexicon Pharmaceuticals, Inc. discussing research presented at the 79th American Diabetes Association (ADA) Scientific Sessions, San Francisco] Press Release CohBar, Inc. announced that it will present its data on a family of novel analogs of a peptide encoded in mitochondrial DNA showing beneficial effects on glucose tolerance and weight loss in an animal model of type 2 diabetes. [Press release from CohBar, Inc. discussing research presented at the 79th American Diabetes Association (ADA) Scientific Sessions, San Francisco] Press Release | |
| |
INDUSTRY NEWSOver time, researchers have observed that some patients develop autoimmune disorders following cancer immunotherapy. The Parker Institute for Cancer Immunotherapy, JDRF and The Leona M. and Harry B. Helmsley Charitable Trust announced a collaborative research initiative to better understand this phenomenon and to identify the causes of type 1 diabetes. [Parker Institute for Cancer Immunotherapy] Press Release US FDA Accepts New Drug Application for Triple Combination Tablet for Adults with Type 2 Diabetes The FDA has accepted the New Drug Application for the investigational fixed-dose combination tablet of empagliflozin, linagliptin and metformin extended release for the treatment of adults with type 2 diabetes, Boehringer Ingelheim and Eli Lilly and Company announced. [Eli Lilly and Company] Press Release BioXcel Therapeutics, Inc. announced an update of its immuno-oncology program for BXCL701, an orally-available systemic innate-immune activator with dual mechanisms of action. [BioXcel Therapeutics, Inc.] Press Release Afrezza® (Insulin Human) Inhalation Powder Approved in Brazil MannKind Corporation and BIOMM SA announced that Afrezza® Inhalation Powder, an ultra rapid-acting mealtime insulin to improve glycemic control in adult patients with diabetes mellitus, has been registered by the Brazilian Health Regulatory Agency. [MannKind Corporation] Press Release BeiGene, Ltd. announced that the China National Medical Products Administration has accepted the supplemental import drug application for ABRAXANE®, in combination with gemcitabine, as a first-line treatment of patients with metastatic adenocarcinoma of the pancreas. [BeiGene, Ltd.] Press Release The approval by the Swedish Medical Products Agency entails that ReGenerate-1, with Diamyd Medical’s GABA-based investigational drug Remygen®, will be expanded from the original two treatment arms encompassing Remygen® administration, with a third treatment arm in which 12 patients receive Remygen® in combination with the GABA receptor modulator Alprazolam. [Diamyd Medical AB (PR Newswire Association LLC)] Press Release £1.2 Million Grants Fund New Research Projects to Tackle Pancreatic Cancer Seven new innovative research projects tackling pancreatic cancer will start this year, thanks to £1.2M funding from Pancreatic Cancer Research Fund. This is the fourth year that the charity has been able to allocate over £1 million for research projects and brings its project portfolio spend to over £9 million. [Pancreatic Cancer Research Fund] Press Release | |
| |
POLICY NEWSCongress Weighs Dropping Ban on Altering the DNA of Human Embryos Used for Pregnancies A congressional committee is expected to vote to drop a ban on altering the genomes of human embryos intended for pregnancies, which could open the door to creating babies with genetic material from three people or with genomes that have been modified in a way that would be inherited by their descendants, as China’s “CRISPR babies” were. [STAT News] Editorial US Science Academy Approves Plan to Oust Sexual Harassers The US National Academy of Sciences has approved an amendment to its by-laws that allows its governing council to expel members for misconduct, including proven cases of sexual harassment. [Nature News] Editorial
| |
EVENTSNEW Keystone Symposia: A Gut-Systemic Perspective for Metabolic Disease Visit our events page to see a complete list of events in the community.
| |
JOB OPPORTUNITIESScientist – Genetic and Genomic Epidemiology (International Agency for Research on Cancer) Postdoctoral Fellow – Preclinical Cancer Research (Karolinska Institutet) Postdoctoral Position – Lung and Pancreatic Cancers (University of California, San Francisco) Professor – Diabetes Research (University of Tennessee Health Science Center) Postdoctoral Fellowship – Pancreatic Cancer (Oregon Health and Science University) Postdoctoral Fellowship – Regenerative Medicine (Cornell University) Research Positions – Pancreatic Beta-Cells (Université de Montréal) Postdoctoral Fellow – Neuroscience and Diabetes (The Child Health Institute of New Jersey) Recruit Top Talent: Reach potential candidates by posting your organization’s career opportunities on the Connexon Creative Job Board at no cost.
| |
Have we missed an important article or publication in Pancreatic Cell News? Click here to submit! Comments or suggestions? Submit your feedback here. | |
|